BCM
KYNB

BlueCrest Capital Management’s Kyntra Bio KYNB Stock Holding History

BlueCrest Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-530
Closed -$490K – 453
2019
Q3 		$490K Sell
530
-1
-0.2% -$1.1K 0.03% 268
2019
Q2 		$600K Buy
+531
New +$581K 0.04% 197

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlueCrest Capital Management's KYNB Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Kyntra Bio (KYNB) in Q4 2019, closing a stake of 530 shares — an estimated $490K sold.

BlueCrest Capital Management first reported a position in KYNB in Q2 2019 and held it in 2 quarters. The position peaked at $600K in Q2 2019. 213 funds tracked by Wall St. Rank hold KYNB as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Kyntra Bio position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 530 Kyntra Bio shares in Q4 2019, an estimated $490K.
  • BlueCrest Capital Management first reported a position in Kyntra Bio in Q2 2019 and held it in 2 quarters.
  • BlueCrest Capital Management's Kyntra Bio position peaked at $600K in Q2 2019.
  • 213 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.